Peppermint oil enhances cyclosporine oral bioavailability in rats: Comparison with D-α-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole

Journal of Pharmaceutical Sciences

Volumn 91, Issue 1, 2002, Pages 77-90

  Wacher, Vincent J ^a,b   Wong, Susan ^a   Wong, Harrison T ^a  

^a AvMax Inc   (United States)

^b Ontogen Corporation   (United States)

Author keywords

Bioavailability; Cyclosporine; Ketoconazole; Peppermint; TPGS

Indexed keywords

ALPHA TOCOPHEROL; CORN OIL; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A; DEXTRO ALPHA TOCOPHERYL POLY(ETHYLENE GLYCOL 100)SUCCINATE; DRUG VEHICLE; KETOCONAZOLE; PEPPERMINT OIL; SUCCINIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; GRAFT REJECTION; INTESTINE ABSORPTION; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; RAT;

EID: 0036141738     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10008     Document Type: Article

References (56)

1. Cyclosporin clinical pharmacokinetics
2. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients- A concentration-controlled comparison with the commercial formulation
3. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - A multicenter investigation in kidney transplant patients
4. Reduced inter-and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjugation with fasting, low-fat meals or high-fat meals
5. Development of Sang-35: A cyclosporine formulation bioequivalent to Neoral
6. Comparison of two cyclosporine formulations in healthy volunteers: Bioequivalence of the new Sang-35 formulation and Neoral
7. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method
8. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation
9. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
10. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine
11. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
12. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazole in stable adult kidney transplants
13. Relative bioavailability of Neoral versus Sandimmune in the presence of a P450IIIA and a P-glycoprotein inhibitor
14. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation
15. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A, in vitro-in vivo correlation
16. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporin A
17. 6′, 7′Dihydroxybergamottin in grapefruit and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein
18. The effect of tocopheryl polyethyleneglycol-1000-succinate (TPGS) on oral cyclosporine absorption in an unrestrained rat model
19. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers
20. Enhanced oral cyclosporine absorption with watersoluble vitamin E early after liver transplantation
21. Product Monograph
22. Characteristics of d-α-tocopheryl PEG 1000 succinate for applications as an absorption enhancer in drug delivery systems
23. Enhancement of cyclosporin A solubility by d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS)
24. Inhibition of P-glycoprotein by d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS)
25. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability
26. Effects of peppermint oil and caraway oil on gastroduodenal motility
27. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: A prospective, randomized trial
28. Peppermint oil for the irritable bowel syndrome: Multicenter trial
29. Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride. A multicenter, reference-controlled double-blind equivalence study
30. Does peppermint oil relieve spasm during barium enema?
31. Solid-phase extraction and liquid chromatography for improved assay of cyclosporine in whole blood or plasma
32. Time-course of cyclosporine and its metabolites in blood, liver and spleen of naive Lewis rats: Comparison with preliminary data obtained in transplanted animals
33. Cyclosporine metabolism by P450IIIA in rat enterocytes - Another determinant of oral bioavariability?
34. Analysis and characterization of enzymes
35. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding
36. The carbon monoxide binding pigment of liver microsomes II. Solubilization, purification and properties
37. Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution in rats
38. Apparent dose-dependent oral absorption of cyclosporin A in rats
39. Bioavailability assessment of cyclosporine in the rat. Influence of route of administration
40. Enhancing effect of essential oils on the penetration of 5-fluorouracil through rat skin
41. Transbuccal permeation of a nucleoside analog, dideoxycytidine: Effects of menthol as a permeation enhancer
42. Effect of menthol and related terpenes on the percutaneous absorption of propranolol across excised hairless mouse skin
43. Absorption kinetics of cyclosporin in the rat
44. Dose-dependent absorption and linear disposition of cyclosporin A in rat
45. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporine A oxidase) in primary cultures of human hepatocytes and in liver microsomes
46. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats
47. Effect of ketoconazole on cyclosporine dose in healthy dogs
48. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats and humans
49. Species differences in the hepatic and intestinal metabolism of cyclosporine
50. Metabolism and transport of the immunosuppressant sirolimus in the small intestine
51. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability
52. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: Evidence of cytochrome P-450 3A and P-glycoprotein induction
53. Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia
54. A novel cytochrome P450 3A isoenzyme in rat intestinal microsomes